XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Additions and Returns of Product Rights (Tables)
 6 Months Ended
Jun. 30, 2022
Business Combinations [Abstract]  
Schedule of Business Acquisitions by Acquisition, Contingent Consideration The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.
Balance at December 31, 2021
$6,515,627 
Cash payment of royalty during the period(501,505)
Change in fair value of contingent consideration included in operating expenses(294,119)
Contingent consideration earned and accrued in operating expenses276,350 
Balance at June 30, 2022
$5,996,353 
The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.
Balance at January 3, 2022$3,946,716 
Cash payment of royalty during the period— 
Change in fair value of contingent consideration included in operating expenses362,453 
Contingent consideration earned and accrued in operating expenses373,973 
Balance at June 30, 2022
$4,683,142 
Schedule of Dissolution Payments
The dissolution payments from Clinigen are reflected as revenue from discontinued operations. The Company did not incur expenses associated with these payments from Clinigen.
Three months ended June 30,Six months ended June 30,
2022202120222021
Revenues$— $498,807 $— $994,217 
Income from discontinued operations$— $498,807 $— $994,217